Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1961 1
1968 3
1973 1
1983 3
1985 1
1986 2
1988 2
1989 2
1992 2
1993 1
1994 3
1995 2
1996 2
1997 1
1998 2
1999 4
2000 5
2001 4
2002 5
2003 5
2004 1
2005 8
2006 3
2007 5
2008 7
2009 14
2010 10
2011 14
2012 8
2013 12
2014 16
2015 18
2016 14
2017 13
2018 14
2019 18
2020 19
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

236 results
Results by year
Filters applied: . Clear all
Page 1
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Liu E, et al. Among authors: dotti g. Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20. Leukemia. 2018. PMID: 28725044 Free PMC article.
Interleukin-23 engineering improves CAR T cell function in solid tumors.
Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G, Xu Y. Ma X, et al. Among authors: dotti g. Nat Biotechnol. 2020 Apr;38(4):448-459. doi: 10.1038/s41587-019-0398-2. Epub 2020 Feb 3. Nat Biotechnol. 2020. PMID: 32015548 Free PMC article.
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Ramos CA, et al. Among authors: dotti g. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23. J Clin Oncol. 2020. PMID: 32701411 Clinical Trial.
Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors.
Fucà G, Reppel L, Landoni E, Savoldo B, Dotti G. Fucà G, et al. Among authors: dotti g. Clin Cancer Res. 2020 Jun 1;26(11):2444-2451. doi: 10.1158/1078-0432.CCR-19-1835. Epub 2020 Feb 3. Clin Cancer Res. 2020. PMID: 32015021 Free PMC article. Review.
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, Tiruthani K, Mirlekar B, Michaud D, Greene K, Herrera SG, Xu Y, Sun C, Chen Y, Ma X, Ferrone CR, Pylayeva-Gupta Y, Yeh JJ, Liu R, Savoldo B, Ferrone S, Dotti G. Du H, et al. Among authors: dotti g. Cancer Cell. 2019 Feb 11;35(2):221-237.e8. doi: 10.1016/j.ccell.2019.01.002. Cancer Cell. 2019. PMID: 30753824 Free PMC article.
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, Sun W, Lin J, Wang T, Fine J, Cheng H, Dotti G, Huang P, Gu Z. Zhang X, et al. Among authors: dotti g. Adv Mater. 2018 May;30(22):e1707112. doi: 10.1002/adma.201707112. Epub 2018 Apr 14. Adv Mater. 2018. PMID: 29656492
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS. Heczey A, et al. Among authors: dotti g. Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12. Nat Med. 2020. PMID: 33046868 Clinical Trial.
236 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page